SPOTLIGHT: Abbott teams with Genentech


Abbott Laboratories and Genentech have announced a new collaboration to develop and sell two cancer therapies. The two Abbott drugs-ABT-263 and ABT-869-have been in Phase I trials. No financial terms were disclosed in the announcement. Report